FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023878206> ?p ?o ?g. }

• W2023878206 endingPage "2463" @default.
• W2023878206 startingPage "2457" @default.
• W2023878206 abstract "Despite trials demonstrating its efficacy, many physicians harbor concerns regarding the use of natalizumab in the treatment of patients with refractory Crohn’s disease (CD). The purpose of this study was to perform a descriptive analysis of a series of CD patients not currently enrolled in a clinical trial. A retrospective case review of patients treated with natalizumab at 6 sites in Massachusetts: Boston Medical Center, Beth Israel Deaconess Medical Center, Brigham & Women’s Hospital, Lahey Clinic, Massachusetts General Hospital, and UMass Medical Center. Data on 69 CD patients on natalizumab were collected. At the start of treatment, patients’ disease duration was 12 years. A high proportion of patients were women (68%), presented with perianal disease (65%) and upper gastrointestinal tract involvement (14%). Prior nonbiologic therapies were steroids (96%), thiopurines (94%), antibiotics (74%), methotrexate (58%), and at least two anti-tumor necrosis factor agent failures (81%). Sixty-nine percent (44 of 64 patients) with available medical evaluation had a partial or complete clinical response. Loss of response was 13% after an average of 1 year of treatment. Adverse events were infusion reactions, headaches, fever, and infections. No case of progressive multifocal leukoencephalopathy was observed. In our clinical experience outside the context of a clinical trial, natalizumab is largely reserved for CD patients with extensive ileocolonic disease who have failed conventional immunosuppressants and of at least 2 anti-tumor necrosis factor agents. This drug is, however, well tolerated and offers significant clinical improvement for more than a year in one-third of these difficult-to-treat CD patients." @default.
• W2023878206 created "2016-06-24" @default.
• W2023878206 creator A5013055903 @default.
• W2023878206 creator A5021150303 @default.
• W2023878206 creator A5025963888 @default.
• W2023878206 creator A5029716989 @default.
• W2023878206 creator A5031219160 @default.
• W2023878206 creator A5047399450 @default.
• W2023878206 creator A5054227961 @default.
• W2023878206 creator A5056934737 @default.
• W2023878206 creator A5060108766 @default.
• W2023878206 creator A5073750919 @default.
• W2023878206 creator A5075621986 @default.
• W2023878206 creator A5082756364 @default.
• W2023878206 creator A5088240942 @default.
• W2023878206 date "2013-10-01" @default.
• W2023878206 modified "2023-10-17" @default.
• W2023878206 title "Efficacy and Safety of Natalizumab in Crohn’s Disease Patients Treated at 6 Boston Academic Hospitals" @default.
• W2023878206 cites W1983511886 @default.
• W2023878206 cites W1994311738 @default.
• W2023878206 cites W1995385281 @default.
• W2023878206 cites W2000379621 @default.
• W2023878206 cites W2004039287 @default.
• W2023878206 cites W2006360844 @default.
• W2023878206 cites W2017295150 @default.
• W2023878206 cites W2022661087 @default.
• W2023878206 cites W2025565161 @default.
• W2023878206 cites W2029110830 @default.
• W2023878206 cites W2044022462 @default.
• W2023878206 cites W2069205998 @default.
• W2023878206 cites W2106747769 @default.
• W2023878206 cites W2112635226 @default.
• W2023878206 cites W2118232932 @default.
• W2023878206 cites W2138223843 @default.
• W2023878206 cites W2159061752 @default.
• W2023878206 cites W2162766966 @default.
• W2023878206 cites W3149527659 @default.
• W2023878206 doi "https://doi.org/10.1097/mib.0b013e3182a32a0d" @default.
• W2023878206 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23962896" @default.
• W2023878206 hasPublicationYear "2013" @default.
• W2023878206 type Work @default.
• W2023878206 sameAs 2023878206 @default.
• W2023878206 citedByCount "23" @default.
• W2023878206 countsByYear W20238782062014 @default.
• W2023878206 countsByYear W20238782062015 @default.
• W2023878206 countsByYear W20238782062016 @default.
• W2023878206 countsByYear W20238782062017 @default.
• W2023878206 countsByYear W20238782062018 @default.
• W2023878206 countsByYear W20238782062019 @default.
• W2023878206 countsByYear W20238782062020 @default.
• W2023878206 countsByYear W20238782062021 @default.
• W2023878206 crossrefType "journal-article" @default.
• W2023878206 hasAuthorship W2023878206A5013055903 @default.
• W2023878206 hasAuthorship W2023878206A5021150303 @default.
• W2023878206 hasAuthorship W2023878206A5025963888 @default.
• W2023878206 hasAuthorship W2023878206A5029716989 @default.
• W2023878206 hasAuthorship W2023878206A5031219160 @default.
• W2023878206 hasAuthorship W2023878206A5047399450 @default.
• W2023878206 hasAuthorship W2023878206A5054227961 @default.
• W2023878206 hasAuthorship W2023878206A5056934737 @default.
• W2023878206 hasAuthorship W2023878206A5060108766 @default.
• W2023878206 hasAuthorship W2023878206A5073750919 @default.
• W2023878206 hasAuthorship W2023878206A5075621986 @default.
• W2023878206 hasAuthorship W2023878206A5082756364 @default.
• W2023878206 hasAuthorship W2023878206A5088240942 @default.
• W2023878206 hasBestOaLocation W20238782061 @default.
• W2023878206 hasConcept C126322002 @default.
• W2023878206 hasConcept C141071460 @default.
• W2023878206 hasConcept C151730666 @default.
• W2023878206 hasConcept C195910791 @default.
• W2023878206 hasConcept C197934379 @default.
• W2023878206 hasConcept C203014093 @default.
• W2023878206 hasConcept C2777138892 @default.
• W2023878206 hasConcept C2778260677 @default.
• W2023878206 hasConcept C2779134260 @default.
• W2023878206 hasConcept C2779280984 @default.
• W2023878206 hasConcept C2779343474 @default.
• W2023878206 hasConcept C2780640218 @default.
• W2023878206 hasConcept C2780644213 @default.
• W2023878206 hasConcept C2781004633 @default.
• W2023878206 hasConcept C535046627 @default.
• W2023878206 hasConcept C71924100 @default.
• W2023878206 hasConcept C86803240 @default.
• W2023878206 hasConceptScore W2023878206C126322002 @default.
• W2023878206 hasConceptScore W2023878206C141071460 @default.
• W2023878206 hasConceptScore W2023878206C151730666 @default.
• W2023878206 hasConceptScore W2023878206C195910791 @default.
• W2023878206 hasConceptScore W2023878206C197934379 @default.
• W2023878206 hasConceptScore W2023878206C203014093 @default.
• W2023878206 hasConceptScore W2023878206C2777138892 @default.
• W2023878206 hasConceptScore W2023878206C2778260677 @default.
• W2023878206 hasConceptScore W2023878206C2779134260 @default.
• W2023878206 hasConceptScore W2023878206C2779280984 @default.
• W2023878206 hasConceptScore W2023878206C2779343474 @default.
• W2023878206 hasConceptScore W2023878206C2780640218 @default.
• W2023878206 hasConceptScore W2023878206C2780644213 @default.
• W2023878206 hasConceptScore W2023878206C2781004633 @default.
• W2023878206 hasConceptScore W2023878206C535046627 @default.

• next